Inclusion Criteria:

- Adult patients, >/= 16 years of age

- Histologically confirmed metastatic melanoma (surgically incurable and unresectable
stage IIIC or stage IV; AJCC) with BRAF V600 mutation determined by Cobas 4800 BRAF
Mutation Test

- Patients may or may not have received prior systemic therapy for metastatic melanoma

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Adequate hematologic, renal and liver function

Exclusion Criteria:

- Evidence of symptomatic CNS lesions, use of steroids or anti-seizure medications for
treatment of brain metastases prior to the first administration of RO5185426

- Previous malignancy (other than melanoma) within the past 2 years, except for treated
and controlled basal or squamous cell carcinoma of the skin or carcinoma in-situ of
the cervix

- Concurrent administration of any anti-cancer therapies other than those administered
in the study

- Clinically significant cardiovascular disease or event within the 6 months prior to
first administration of study drug

- Refractory nausea or vomiting, external biliary shunt, or significant bowel resection
that would preclude adequate absorption